By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Practice > Clinical Updates > Biogen-Denali Parkinson’s Drug Fails Phase 2 Trial, Highlighting Treatment Development Challenges
Clinical UpdatesPractice

Biogen-Denali Parkinson’s Drug Fails Phase 2 Trial, Highlighting Treatment Development Challenges

GMJ
Last updated: 25/05/2026 16:04
By
GMJ Practice Desk
Share
5 Min Read
Pharmaceutical research laboratory with Parkinson's disease drug development
Biogen and Denali's experimental Parkinson's therapy failed Phase 2 trial endpoints, highlighting ongoing challenges in neurodegenerative disease drug development. The setback affects over 10 million patients worldwide seeking disease-modifying treatments. — Photo: www.kaboompics.com / Pexels
SHARE
🎧 Listen to this article3:41 min · 521 words · GMJ Audio

Updated 25/05/2026

Contents
  • Industry Impact and Investment Concerns
  • Alternative Research Approaches
    • Key takeaways
  • Frequently asked questions
    • Why do so many Parkinson’s disease drugs fail in clinical trials?
    • What treatment options are currently available for Parkinson’s patients?
    • Are there other promising Parkinson’s treatments in development?
2 min read|464 words

A closely watched experimental therapy for Parkinson’s disease has failed to demonstrate clinical benefit in a pivotal Phase 2 trial, dealing a setback to efforts to develop new treatments for the progressive neurological disorder. Biogen and Denali Therapeutics announced that their investigational drug did not slow disease progression compared to placebo in patients with early-stage Parkinson’s disease.

The randomized, double-blind study enrolled patients with early-stage Parkinson’s disease to evaluate whether the experimental therapy could slow motor and cognitive decline. The failure adds to a growing list of unsuccessful attempts to develop disease-modifying treatments for Parkinson’s disease. Current approved therapies primarily manage symptoms rather than addressing the underlying neurodegeneration, leaving patients with limited long-term treatment options.

Industry Impact and Investment Concerns

The negative results reflect broader challenges in neurodegenerative disease drug development, where clinical trials face high failure rates despite promising preclinical data. Biogen’s stock declined following the announcement, while Denali Therapeutics indicated it would continue development of other neurological programs.

Submit Your Paper
GMJ_Submit_Banner
🎙️ Related Podcast Episodes
🎧 #9 Leprosy in 2026: Bridging Medical Cure and Social Inclusion – WHO World Leprosy Day Message · 18m
🎧 #32 | GMJ Podcast | Launch of the Georgian Medical Journal — A New International Platform for Medical Science · 5m
🎧 #25 | WHO Warns: Childhood Hearing Loss Must Be Addressed Early · 19m
🎧 #21 | WHO Issues New Guidance on Novel Snakebite Treatments · 14m
🎧 #15 | WHO: One in Two People Facing Cataract Blindness Still Need Access to Surgery · 21m

Alternative Research Approaches

Despite this setback, several other Parkinson’s disease treatments remain in development across the pharmaceutical industry. Research teams at major academic medical centers continue investigating novel approaches including gene therapy, stem cell treatments, and precision medicine strategies targeting specific genetic variants.

The Michael J. Fox Foundation and other research organizations maintain funding for multiple investigational programs, with particular emphasis on biomarker development to improve trial design and patient selection in future studies.

Key takeaways

  • Biogen-Denali experimental Parkinson’s therapy failed to meet primary endpoints in Phase 2 trial
  • Current approved treatments focus on symptom management rather than disease modification
  • Multiple alternative research approaches including gene therapy remain under investigation

Frequently asked questions

Why do so many Parkinson’s disease drugs fail in clinical trials?

Parkinson’s disease involves complex neurobiological mechanisms that are not fully understood, making it difficult to design effective interventions. Additionally, the disease progresses slowly, requiring long trial durations to detect meaningful clinical benefits.

What treatment options are currently available for Parkinson’s patients?

Current FDA-approved treatments include levodopa, dopamine agonists, and MAO-B inhibitors, which help manage motor symptoms. Deep brain stimulation surgery is also available for advanced cases, but no treatments currently slow or stop disease progression.

Are there other promising Parkinson’s treatments in development?

Yes, multiple approaches remain under investigation including alpha-synuclein immunotherapies, gene therapies targeting GBA mutations, and precision medicine strategies. Several programs are currently in Phase 2 and Phase 3 trials.

The pharmaceutical industry’s continued investment in Parkinson’s research despite repeated setbacks reflects both the significant unmet medical need and the potential market opportunity for an effective disease-modifying treatment. Future trials will likely incorporate lessons learned from recent failures, including improved biomarker strategies and more refined patient selection criteria to increase the probability of clinical success.

Source: STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more

Was this article helpful?

Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →

Related Coverage

Community Walking Groups Show Mental Health Benefits for Bereaved AdultsJul 8, 2026
Ebola outbreak in DRC and Uganda spreads to new regions; CDC updates response strategyJul 8, 2026
Bacteriophage Therapy Saves Patient from Antibiotic-Resistant Skull InfectionJul 7, 2026
AI Drug Development Faces Reality Check as BigHat CEO Debunks Industry HypeJul 7, 2026
Related reference
  • Lung Cancer · Condition
PG
Written by
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, GMJ News
Full profile →  ·  ORCID 0000-0001-7609-4515
Medical disclaimer. This article is health journalism intended for general information. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. Always seek your physician's advice regarding any medical condition.
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
Get the GMJ News digest
Evidence-based health journalism in your inbox. No spam; unsubscribe anytime.
TAGGED:Biogenclinical trialsdrug developmentneurodegenerative disordersParkinson's disease
Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByGMJ Practice Desk
Follow:
GMJ Practice Desk is part of GMJ News, the newsroom of the Georgian Medical Journal (gmj.ge), published by the Public Health Institute of Georgia. Every article is editorially reviewed before publication.
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
PFAS ‘Forever Chemicals’ Persist in Ski Wax Rooms Despite Regulatory Bans

New research reveals PFAS 'forever chemicals' persist in ski wax facilities years…

Community Walking Groups Show Mental Health Benefits for Bereaved Adults

A community walking group in Darwen demonstrates how peer-supported physical activity provides…

Ebola outbreak in DRC and Uganda spreads to new regions; CDC updates response strategy

The Democratic Republic of the Congo and Uganda report active Ebola transmission…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Digital blood pressure monitor with smartphone showing health data transmissionIllustrative image · Photo by SHVETS production on Pexels (Pexels License)
Clinical UpdatesNew StudiesPracticeResearch Digest

Home Blood Pressure Monitoring Reduces Heart Attack and Stroke Risk by 36%

By
GMJ Practice Desk
26/06/2026
Medical illustration showing hepatitis delta virus structure and liver cellsIllustrative image · Photo by Marta Branco on Pexels (Pexels License)
Clinical UpdatesPractice

FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection

By
GMJ Practice Desk
16/06/2026
Modern rooftop intensive care unit with natural lighting and outdoor environment at King's College Hospital
Clinical UpdatesPractice

World’s First Rooftop ICU Opens in London to Study Nature’s Role in Patient Recovery

By
GMJ Practice Desk
11/06/2026
Medical ultrasound equipment used for intestinal imaging in Crohn's disease monitoring
Clinical UpdatesPractice

New International Guidelines Standardize Ultrasound Monitoring for Post-Surgery Crohn’s Disease Patients

By
GMJ Practice Desk
30/05/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up